In acute myeloid leukaemia (AML), the cell of origin, nature and biological consequences of initiating lesions, and order of subsequent mutations remain poorly understood, as AML is typically diagnosed without observation of a pre-leukaemic phase. Here, highly purified haematopoietic stem cells (HSCs), progenitor and mature cell fractions from the blood of AML patients were found to contain recurrent DNMT3A mutations (DNMT3A mut ) at high allele frequency, but without coincident NPM1 mutations (NPM1c) present in AML blasts. DNMT3A mut -bearing HSCs showed a multilineage repopulation advantage over non-mutated HSCs in xenografts, establishing their identity as pre-leukaemic HSCs. Pre-leukaemic HSCs were found in remission samples, indicating that they survive chemotherapy. Therefore DNMT3A mut arises early in AML evolution, probably in HSCs, leading to a clonally expanded pool of pre-leukaemic HSCs from which AML evolves. Our findings provide a paradigm for the detection and treatment of pre-leukaemic clones before the acquisition of additional genetic lesions engenders greater therapeutic resistance.
In acute myeloid leukaemia (AML), the cell of origin, nature and biological consequences of initiating lesions, and order of subsequent mutations remain poorly understood, as AML is typically diagnosed without observation of a pre-leukaemic phase. Here, highly purified haematopoietic stem cells (HSCs), progenitor and mature cell fractions from the blood of AML patients were found to contain recurrent DNMT3A mutations (DNMT3A mut ) at high allele frequency, but without coincident NPM1 mutations (NPM1c) present in AML blasts. DNMT3A mut -bearing HSCs showed a multilineage repopulation advantage over non-mutated HSCs in xenografts, establishing their identity as pre-leukaemic HSCs. Pre-leukaemic HSCs were found in remission samples, indicating that they survive chemotherapy. Therefore DNMT3A mut arises early in AML evolution, probably in HSCs, leading to a clonally expanded pool of pre-leukaemic HSCs from which AML evolves. Our findings provide a paradigm for the detection and treatment of pre-leukaemic clones before the acquisition of additional genetic lesions engenders greater therapeutic resistance.
There is overwhelming evidence that virtually all cancers are clonal and represent the progeny of a single cell [1] [2] [3] , but the evolutionary trajectory that leads from the first somatic mutation to the eventual development of cancer is not well mapped. The simplest models predict that each newly acquired somatic mutation confers selective advantage to drive successive waves of clonal expansion, with the fittest clone becoming dominant. However, the modern era of cancer genomics has exposed a more complex clonal architecture in many tumour types 4 , where multiple genetically distinct subclones co-exist with the dominant clone 5, 6 . Comparison of diagnostic and recurrent/metastatic samples obtained from the same patient has established that the latter frequently do not evolve from the dominant clone, but instead can be traced either to a minor subclone present at diagnosis, or to a putative, undetected ancestral clone [7] [8] [9] [10] [11] [12] [13] [14] [15] . Thus, a clear understanding of the genomic landscape of tumours is required to devise targeting strategies that eliminate not only the dominant clone, but also the subclonal reservoirs from which recurrence can arise.
Although the clonal composition of cancer lineages within individual tumours is coming into focus, the very first steps in cancer development remain poorly defined. Early and possibly initiating mutations have been identified from analysis of pre-neoplastic lesions in breast 16 , lung 17 , skin 18 and colon cancer 19 , as well as from studies of AML cases that evolved from a prior myelodysplastic syndrome (MDS) 20 . However, key questions remain unanswered. In particular, can clinically relevant clones be traced back to a non-tumorigenic cell? Do pre-cancerous ancestral clones persist after tumour development? If so, are they present in the diagnostic sample, and do they survive treatment and persist in remission samples?
Human leukaemia is a disease model particularly suited to addressing these fundamental questions, due to the depth of our understanding of normal haematopoiesis and the availability of functional assays and analytic tools that allow examination of phenotypically defined populations at the single-cell level 21 . In AML, a subset of cases evolve from a preceding clinically overt phase such as MDS or chronic myeloid leukaemia (CML), characterized by clonal expansion of one or more blood lineages 22, 23 . The founder mutations present in pre-leukaemic cells are retained in the AML blasts, implicating them as putative initiating events and establishing clonal expansion as the first step in leukaemogenesis. Interestingly, somatic mutations in some leukaemia-associated genes such as TET2 have also been linked to multilineage clonal haematopoiesis in ageing healthy individuals 24 . Insight into the phenotype of the normal cell from which clonal expansion can initiate was first provided by pioneering studies in CML, which demonstrated that BCR-ABL1 arises in a multipotential HSC 25 . However, for the majority of AML cases that arise de novo without any prior clinical perturbations, insight into the cellular context and functional consequences of the earliest genetic lesions requires identification and examination of ancestral cells within the diagnostic sample. Recent studies have found that only a subset of mutations contained in AML blasts were present in HSCenriched cell fractions isolated from AML patient samples, and that these cells were capable of non-leukaemic differentiation 26, 27 . Here we establish that these ancestral pre-leukaemic HSCs present at diagnosis are able to regenerate the entire haematopoietic hierarchy while possessing competitive repopulation advantage over non-leukaemic HSCs leading to clonal expansion. These pre-leukaemic HSCs are found in a high proportion of AML patients that carry mutations in DNMT3A and IDH2, and unlike AML blasts, they survive induction chemotherapy and persist in the bone marrow at remission, providing a potential reservoir for leukaemic progression. (Fig. 1a) . Unexpectedly, in 3 of these 4 patients, DNMT3A mut was detected in T cells at a low allele frequency (1-20%). Other genetic alterations, including NPM1c, were found only in peripheral blood but not in T-cell samples, ruling out AML cell contamination of cultured T cells. To estimate the proportion of AML cases with DNMT3A mut -bearing T cells, 71 additional samples, taken at diagnosis from patients with normal cytogenetics, were screened by Sanger sequencing for DNMT3A mut along with other common AML mutations (Supplementary Table 4 ). Consistent with published data [29] [30] [31] , 17 out of 71 AML samples (24%) carried mutations in DNMT3A, and 15 of these 17 (88%) also carried NPM1c. For these 17 patients, the allele frequency of DNMT3A mut and NPM1c in CD33 1 blasts, as well as corresponding freshly isolated T-cell controls, was measured by droplet digital PCR (ddPCR) at a sensitivity of 1 mutated allele in 1,000 reference alleles. Whereas both DNMT3A mut and NPM1c were always present in blasts at similar allele frequency, DNMT3A mut with no evidence of NPM1c was detected in T cells from 12 of these 17 patients (70.5%) (Fig. 1b) . In addition, FLT3 internal tandem duplications (FLT3-ITD) were detected in blasts, but not in the T cells of two patients bearing this mutation (Extended Data Fig. 1 ). These data reveal the sequential order of mutation acquisition in these patients, with DNMT3A mut arising earlier in leukaemogenesis than NPM1c and FLT3-ITD, a conclusion predicted from recent studies on bulk AML blasts showing that NPM1c and FLT3-ITD occur late and are the only genes recurrently mutated in DNMT3A mut AML 15, 28, 32 . Moreover, our findings establish that DNMT3A mut occurs in an ancestral cell that gives rise to both T cells and the dominant AML clone present at diagnosis.
DNMT3A mut HSCs undergo multilineage differentiation
To gain insight into the properties of the ancestral cell within which DNMT3A mut first arises, we examined additional non-leukaemic haematopoietic cell populations from 11 DNMT3A mut /NPM1c AML patients. A high-resolution 12-parameter sorting strategy [33] [34] [35] was used to isolate non-leukaemic haematopoietic stem and progenitor cell populations, including haematopoietic stem cells/multipotent progenitors (HSCs/ MPPs), multilymphoid progenitors (MLPs), common myeloid progenitors (CMPs), granulocyte monocyte progenitors (GMPs), and megakaryocyte erythroid progenitors (MEPs), as well as mature B, T and natural killer (NK) cells within the CD33 -cell fraction. Together with CD45 dim CD33
1 AML blasts, these highly purified, phenotypically defined normal cell populations were assessed by ddPCR for DNMT3A mut and NPM1c ( Fig. 2 table correspond to the numbers in Supplementary  Table 3 . Somatic mutations in DNMT3A (*R882H; {R137C) were found in both T cells and AML blasts in patients no. 9, 11 and 12. Patient no. 12 also had a low frequency IDH2 mutation ({R140L) in T cells. b, Frequency (%) of DNMT3A mut and NPM1c in freshly isolated CD33 1 blasts (AML) and matched T-cell controls from 17 patients with normal karyotype AML, as determined by droplet digital PCR. For a and b, the length of the bars is proportional to the mutant allele frequency (the scale bar under the first column applies to all columns).
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providing further strong evidence that DNMT3A mut precedes NPM1c during leukaemogenesis. Interestingly, in three patients (no. 10, 14, 16), DNMT3A mut was detected in CMPs but not HSCs/MPPs, an outcome consistent with the existence of DNMT3A mut -bearing HSCs below our detection limit that generated a clonally expanded CMP population, or possibly the existence of a preceding lesion in HSCs/MPPs with later acquisition of DNMT3A mut in CMPs. Resolution of this question will require whole-genome sequencing of sorted blast and phenotypically normal populations from patient samples. Our analysis also showed that in 6 out of 11 patients, both DNMT3A mut and NPM1c were found together in MLP and/or GMP populations, pointing to the probable progenitor cell types where overt AML driven by NPM1c arises. Collectively, our findings provide key insights into the leukaemogenic process in human AML and confirm historical predictions from early clonality studies of the existence of a pre-leukaemic state 3, 37 .
Pre-leukaemic HSCs survive chemotherapy
To examine how DNMT3A mut affects population dynamics during leukaemic progression, we undertook temporal analysis of mature and progenitor cells from 5 patients (no. 11, 28, 35, 55, 57) sampled at diagnosis, remission (3 months) or relapse ( ) cell populations, as indicated, isolated from diagnosis (blue), remission (white) and relapse (red) samples of patient no. 11 as determined by droplet digital PCR (ddPCR). At remission, CD33
1 myeloid cells were also analysed. c, Summary of the occurrence of DNMT3A mut and NPM1c in isolated stem/progenitor, mature and blast cell populations from 11 AML patient peripheral blood samples as determined by ddPCR. White, neither DNMT3A mut nor NPM1c detected; grey, DNMT3A mut alone detected; black, both DNMT3A mut and NPM1c detected. NA, no cell population detected; HSC, haematopoietic stem cell; MPP, multipotent progenitor; MLP, multilymphoid progenitor; CMP, common myeloid progenitor; GMP, granulocyte monocyte progenitor; MEP, megakaryocyte erythroid progenitor; NK, natural killer cells. d, Graphic representation of DNMT3A mut allele frequency in sorted cell populations isolated from diagnosis (0 months), early (3) and late (36) remission samples of patient no. 57.
that allowed a comparison of early and late (36 months) remission samples; this revealed a marked increase in DNMT3A mut allele frequency in most cell populations over time (Fig. 2d) . In addition, a small proportion of CD33 1 myeloid cells in the late remission peripheral blood sample contained both DNMT3A mut and the NPM1c mutation found at diagnosis, indicating either regrowth of the diagnostic leukaemic clone or emergence of a new clone following an independent NPM1c mutation event within the pre-leukaemic pool. Collectively, our data indicate that the ancestral cell that bears DNMT3A mut without NPM1c is an HSC/MPP capable of multilineage differentiation. Moreover, these ancestral HSCs/MPPs survive chemotherapy, expand during remission, and might serve as a reservoir for clonal evolution leading to recurrent disease.
Pre-leukaemic HSCs undergo clonal expansion
mut allele frequency in HSCs/MPPs of 30% and 20%, respectively, were transplanted into cohorts of immunodeficient mice using a limiting dilution approach and analysed after 8 and 16 weeks ( Data Fig. 6 ). For patient no. 11, multilineage engraftment was seen in 24 out of 35 mice, giving a calculated frequency of one repopulating HSC in 7.3 3 10 5 cells (Extended Data Fig. 5a ). Only a single graft contained more than 50% CD33
1 myeloid cells, consistent with co-engraftment by a leukaemia stem cell (LSC) that was present at low frequency 38 . We analysed by ddPCR 12 of the multilineage xenografts following 16 weeks of repopulation. Ten of these contained a high proportion of cells bearing DNMT3A mut without NPM1c (mean allele frequency 57%), whereas both DNMT3A mut and NPM1c were present in the single mouse with significant myeloid engraftment (Fig. 3b) . Kinetic analysis demonstrated increasing DNMT3A mut allele frequency in multilineage grafts over time (Fig. 3c) . Similar results were found for patient no. 55 (Extended Data Fig. 5 and data not shown). In contrast, cells from the relapse sample of both patients generated leukaemic grafts and no multilineage grafts (Fig. 3a and data not shown) , consistent with a higher LSC frequency at relapse compared to diagnosis 38 . Together, these data provide evidence that DNMT3A mut occurs in HSCs/ MPPs capable of generating a long-term multilineage lympho-myeloid graft, confirming their designation as pre-leukaemic HSCs 26 . DNMT3A mut also endows pre-leukaemic HSCs with a competitive repopulation advantage over non-mutated HSCs, explaining the clonal expansion of preleukaemic HSCs in patients at the time of diagnosis and during remission. Our xenograft results indicate that when pre-leukaemic HSCs exist at higher frequency than LSCs, non-leukaemic multilineage grafts, rather than leukaemic grafts, are frequently generated. Examination of our historical xenograft data from 264 diagnostic AML samples revealed that 37% did not generate any graft, 40% generated leukaemia, and 23% gave rise to non-leukaemic multilineage grafts (Extended Data Fig. 6 ). Sanger sequencing data was available for 25 samples that generated multilineage grafts (Supplementary Table 4) , and revealed that 10 out of 25 (40%) came from patients bearing DNMT3A mut ; IDH1/IDH2 mutations were present in 12 patients, including three who had both DNMT3A and IDH1/IDH2 mutations (Fig. 4a, b) . It was not possible to determine conclusively whether these xenografts were generated by pre-leukaemic HSCs, as they were not available for mutation testing. To examine whether pre-leukaemic cells also exist in patients with IDH1/IDH2 mutations, we analysed samples from three patients with IDH1 mutation and three patients with IDH2 mutation by high-resolution cell sorting and ddPCR. In four patients, no pattern of preceding mutation was detected in non-leukaemic cell populations. However, in two patients we found IDH2 mutation without NPM1c in a number of progenitor and mature cell populations (Fig. 4c) , indicating that IDH2 mutation might also occur as a pre-leukaemic event.
Our data predict that DNMT3A mutation may occur in healthy adults and pre-date AML diagnosis by months or even years. Through searches of exome sequence databases derived from peripheral blood (https://esp.gs.washington.edu/drupal/) we found that the frequency of the DNMT3A R882H variant (rs147001633) was 0.066% (3 in 4,545). Although this was considered to be a germline variant in this healthy adult cohort, our findings raise the possibility that the mutations detected in these studies may have originated from an HSC/MPP containing an acquired somatic DNMT3A mutation that underwent clonal expansion.
Discussion
Our study provides a number of key insights into the leukaemogenic process in human AML. Our findings establish the sequential order of mutation acquisition for the patients reported here: DNMT3A mut occurs before NPM1c and FLT3-ITD. Additionally, we provide strong evidence for the presence, at diagnosis, of pre-leukaemic HSCs that are ancestral to the dominant AML clone. Based on our data, pre-leukaemic HSCs are prevalent among patients with DNMT3A mut , which account for 
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25% of adult AML cases; additionally, our multilineage engraftment data indicate that pre-leukaemic HSCs may also exist in a proportion of AML patients with IDH2 mutations. Pre-leukaemic progenitors of varying phenotypes have been reported in other types of hematologic malignancies 25, [39] [40] [41] , although functional studies were limited. Our work supports previous studies identifying phenotypic primitive cells that bear only a subset of mutations found in AML blasts 26, 27, 42 . The more precise analysis of highly resolved HSCs and progenitor populations that we have undertaken provides novel insight into the identity and proportional contribution of the stem/progenitor populations that acquire pre-leukaemic lesions. Furthermore, our work demonstrates that DNMT3A mut confers a functional repopulation advantage to preleukaemic HSCs over wild-type HSCs in xenograft assays, which probably underlies the clonal expansion of pre-leukaemic HSCs observed in patients at the time of diagnosis. Our study is consistent with mouse studies showing that HSCs lacking DNMT3A have a competitive growth advantage 43, 44 , and with a recent report predicting that the human DNMT3A mut results in loss of function 45 . Collectively, our results support a model wherein the cell of origin for DNMT3A mut AML is an HSC and the initiating DNMT3A mutation results in the generation of an expanded pool of HSCs and downstream progenitors, within which additional mutations such as NPM1c are acquired, driving progression to AML. In the samples studied here, our findings point to GMP and/or MLP as the likely populations in which NPM1c was acquired. Our experimental design provides a framework for the future identification of other early events in leukaemogenesis, using generation of multilineage xenografts as a surrogate assay to identify AML samples that may contain pre-leukaemic HSCs, and for examining how these changes disrupt normal HSC function, cause clonal expansion and initiate leukaemic development.
Our results have broad clinical implications. Previous studies in T-ALL 46 and B-ALL 7, 11, 14 revealed the existence of genetically diverse subclones at diagnosis. As found originally in these diseases 47 and now in AML, in approximately 50% of patients the relapse clone is not related to the predominant clone at diagnosis, but rather to a minor leukaemic subclone 10, 15 or to a predicted ancestral clone 47 . Our direct demonstration that ancestral clones persist at remission suggests that pre-leukaemic HSCs are resistant to induction chemotherapy, and for some patients they might represent a reservoir from which relapse arises. If future phylogenetic single-cell lineage analysis establishes this possibility, then pre-leukaemic HSCs should be directly targeted to prevent relapse. As new drugs are developed that effectively target mutations in DNMT3A or other genes that give rise to pre-leukaemic HSCs (for example, AG-221, an IDH2 inhibitor), there may be an opportunity to eradicate these pre-leukaemic HSC clones before the acquisition of additional mutations renders them more resistant to therapy. Our findings also support broadening the definition of minimal residual disease to include not only the post-therapy survival of AML blasts and LSCs but also pre-leukaemic HSCs. Practically, this suggests that, for patients with both DNMT3A mut and NPM1c, the residual level of both mutations and not NPM1c alone should be monitored. Finally, our database analysis showing that the DNMT3A R882H variant is present in blood samples from normal adults should stimulate new studies investigating whether pre-leukaemic HSCs are present in healthy individuals and determining the risk of progression to AML; these may in turn enable earlier diagnosis for those patients who present without prior overt haematologic disturbances. Of note, a recent report describes the development of donor-derived leukaemia in a patient 27 months after receiving allogeneic HSCs from an HLA-matched sibling, whose donated peripheral blood cells were later found to carry mutations in IDH2 and DNMT3A at low frequency 48 . Interestingly, the donor remains free of leukaemia 10 years after his stem-cell donation, indicating that the mechanisms underlying the progression from subclinical pre-leukaemic haematopoiesis to overt leukaemia are complex and context-dependent.
METHODS SUMMARY
All patient samples listed in Supplementary Tables 2 and 4 were obtained under Research Ethics Board approval with informed consent. Non-leukaemic stem, progenitor and mature cells were sorted from diagnostic samples and subjected to genomic analysis. Illumina sequencing libraries were constructed and target enrichment was performed using a custom Agilent SureSelect kit (following manufacturer's protocol). Sequencing was conducted on the Illumina HiSeq 2000 platform to an average on target coverage of 2503. Reads were aligned to the reference human genome build hg19 using Novoalign (Novocraft), and a BAM file was produced for each tumour and T-cell pair. Variant calls were made using the genome analysis tool kit (GATK). Significance levels (P values) were determined by chi-square test. Targeted Sanger sequencing and ddPCR were performed for specific point mutations. Primary AML samples were also transplanted in xenograft assays using standard conditions.
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper.
METHODS
Targeted sequencing of leukaemia-associated genes. Genomic DNA was subjected to limited whole-genome amplification (RepliG, Qiagen) to obtain the required amount of input DNA for the SureSelect protocol. Amplified genomic DNA was mechanically sheared using the Covaris M220 Focused-ultrasonicator, and Illumina sequencing adaptors were ligated to fragments to make a sequencing library, which was then hybridized with 120mer biotinylated RNA library baits to capture the regions of interest. Baits were designed to capture the coding sequence of the 103 leukaemia-associated genes listed in Supplementary Table 1 (total target size ,370 kilobases). The targeted regions were pulled out using magnetic streptavidin beads and amplified. The resulting amplified library was quantified and sequenced on the Illumina HiSeq 2000 platform to an average on target coverage of 2503. Reads were aligned to the reference human genome build hg19 using Novoalign (Novocraft) and on-target single nucleotide variants (SNVs) and indels were called using the genome analysis tool kit (GATK). Somatic SNVs were called in AML blasts with a read depth of at least 303. The list of contributors to the gene list is provided in Supplementary Note 1. T cell isolation and expansion from primary AML samples. CD3 1 cells were isolated from peripheral blood AML patient samples using EasySep (Stem Cell Technologies) and re-suspended at a concentration of 1 3 10 7 cells in 2 ml in RPM1 1 10% FBS-HI 1 rhIL-2 (250 IU per mL, Proleukin, Chiron) 1 anti-CD28 antibody (5 mg ml 21 , clone CD28.2, eBioscience). Cells were then added to one well of a 24-well plate that had been pre-coated for 2 h with anti-CD3 antibody (Clone OKT3, eBioscience) and cultured for 4 days at 37 uC with 5% CO 2 . Cells were collected on day 4, resuspended in fresh RPMI 1 10% FBS-HI 1 rhIL2 (250 IU ml
21
) and replated into one well of a six-well plate. Cells were further cultured and expanded for 14-20 days, feeding with fresh full medium containing rhIL-2 (250 IU ml
) every 3-4 days. At the end of T cell expansion, the purity of CD3 1 T cells was checked by flow cytometry. DNA from the cultured T cells was extracted by PureGene Cell kit (Qiagen). Droplet digital PCR (ddPCR). Genomic DNA (25 ng) or amplified DNA (2 ml from a 1:20 dilution of a 16 h RepliG whole-genome amplification) was subjected to ddPCR in a 96-well plate according to the manufacturer's protocol. Each sample was tested in duplicate. The plate was then loaded onto a droplet reader with a two colour FAM/VIC fluorescence detector. The mutant allele frequency was calculated as the fraction of positive droplets divided by total droplets containing a target. The TaqMan probes and primers used for ddPCR are listed in Supplementary Table 5 . To evaluate the detection limits of the ddPCR assay, a standard curve was generated using serial dilutions of DNA with a known mutation frequency mixed with non-mutated DNA. For probes listed in Supplementary Table 5 , the minimum detection level was 1:1,000 (0.1%). Fluorescence activated cell sorting of human stem/progenitor and mature cell populations. Mononuclear cells (10 6 in 100 ml) from peripheral blood or bone marrow of AML patients were stained with the following antibodies (all from BD unless stated otherwise, dilution used and catalogue number in parentheses): anti-CD45RA-FITC (1:25, 555488), anti-CD90-APC (1:50, 561971), anti-CD135-Biotin (1:10, 624008), anti-CD38-PE-Cy7 (1:200, 335790), anti-CD10-Alexa-700 (1:10, 624040), anti-CD7-Pacific Blue (1:50, 642916), anti-CD45-V500 (1:200, 560777), anti-CD34-APC-Cy7 (1:100, custom made by BD, CD34 clone 581), anti-CD34-PerCP-Efluor 710 (1:100, e-Bioscience 46-0344-42), anti-CD33-PECy5 (1:100, Beckman Coulter PNIM2647U), anti-CD19-PE (1:200, 349204), anti-CD3-FITC (1:100, 349201), anti-CD56-Alexafluor 647 (1:100, 557711), and Streptavidin-QD605 (1:200, Invitrogen Q10101MP). Samples from patients no. 1, 10, 11 (remission sample only), 32, 35, and 55 were enriched for CD34 1 cells using a Miltenyi CD34 MicroBead kit according to the manufacturer's protocol before antibody staining. Cells were sorted on a FACS AriaIII to a post-sort purity of .95%. Xenotransplantation assays. Animal experiments were performed in accordance with institutional guidelines approved by the UHN Animal Care Committee. 8 to 12-week-old female NOD/SCID/IL-2Rg c -null (NSG) mice were sublethally irradiated (225 cGy) 6-24 h before transplantation. Mononuclear cells from AML patients were depleted of CD3 1 cells by EasySep (Stem Cell Technologies) before intrafemoral transplantation. Mice were killed 8 or 16 weeks after transplantation and human engraftment in the injected femur and non-injected bone marrow was evaluated by flow cytometry using the following human-specific antibodies (all used at 1:200, all from BD unless stated otherwise, catalogue number in parentheses): anti-CD45-APC (340943), anti-CD19-PE, anti-CD33-PE-Cy5, anti-CD3-FITC, anti-CD14-PE Texas Red (Beckman Coulter PNIM2707U), anti-CD15-Pacific Blue (642917), anti-CD38-PE-Cy7, and anti-CD34-APC-Cy7. The threshold for detection of human engraftment was 0.1% CD45 1 cells. All flow cytometric analysis was performed on the LSRII (BD Biosciences). For limiting dilution assays, the frequency of repopulating cells was calculated using ELDA software 49 . Statistical analysis. For the initial targeted sequencing analysis, 12 independent patient samples were studied to capture the biologic diversity of AML. For validation of the DNMT3A findings, 71 samples were screened to identify at least 15 with DNMT3A mutations, as predicted by the known prevalence of DNMT3A mutation in AML. For limiting dilution analyses, at least 25 xenografts were analysed for each patient sample to ensure a large enough sample for statistical comparison. No animals or samples were excluded from any analysis. No formal randomization method was applied when assigning animals to different experimental groups. Group allocation and outcome assessment was not done in a blinded manner, including for animal studies. Frequency estimations were generated using the ELDA software, which takes into account whether the assumptions for LDA are met (http://bioinf.wehi.edu.au/software/elda/index.html, provided by the Walter and Eliza Hall Institute) 49 . P values were derived using twotailed Student's t-tests. In each group of data, estimate variation was taken into account and is indicated as standard deviation. For all graphs, *P 5 0.01-0.05, **P 5 0.001-0.01, and ***P , 0.001. ARTICLE RESEARCH
